1. Reis LA, Percy CL, Bunin GR. Cancer incidence and survival among children and adolescents. United States SEER Program. 1975–1995. NIH (Pub. No. 99–4649). Bethesda, MD: National Cancer Institute; 1999. p. 1–15.
2. Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review 1975–2002. Bethesda, MD: National Cancer Institiute; 2005.
3. Gurney JG, Young JL, Roffers SD, Smith MA, Bunin GR. Cancer incidence and survival among children and adolescents: United States SEER Program. 1975–1995 NIH (Pub. 99–4649). Bethesda, MD: National Cancer Institute; 1999. p. 111–24.
4. Horowitz ME, Etcubanas E, Christensen ML, et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol. 1988;6:308–14.
5. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 2004;40:837–44.